

AD-A090 038

ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FR--ETC F/G 6/5  
EFFECT OF LYSOZYME ON THE IMMUNE RESPONSE OF GUINEA PIGS TO THE--ETC(U)  
AUG 80 R F WACHTER, G P BRIGGS

UNCLASSIFIED

NL

1 of 1  
AD-A090 038



END  
DATE  
FILMED  
11-80  
DTIC

## REPORT DOCUMENTATION PAGE

READ INSTRUCTIONS  
BEFORE COMPLETING FORM

1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
	AD-A090038	
4. TITLE (and Subtitle)		5. TYPE OF REPORT & PERIOD COVERED
EFFECT OF LYSOZYME ON THE IMMUNE RESPONSE OF GUINEA PIGS TO THE SOLUBLE PHASE I ANTIGEN OF COXIELLA BURNETII.		9 Interim rept.
7. AUTHOR(s)		6. PERFORMING ORG. REPORT NUMBER
RALPH F. WACHTER, G.P. BRIGGS		
9. PERFORMING ORGANIZATION NAME AND ADDRESS		8. CONTRACT OR GRANT NUMBER(s)
US Army Medical Research Institute of Infectious Disease, Aerobiology Division (SGRD-UIA-E), Fort Detrick, Frederick, Maryland 21701		
11. CONTROLLING OFFICE NAME AND ADDRESS		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
US Army Medical Research and Development Command, Office of the Surgeon General, Department of the Army, Frederick, MD 21701		A841-00-047
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		12. REPORT DATE
12 12		27 Aug 1980
		13. NUMBER OF PAGES
		11
		15. SECURITY CLASS. (of this report)
		UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report)		
Cleared for public release; distribution unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
Reprints bearing assigned AD number will be forwarded upon receipt. To be submitted for publication in the Infection and Immunity Journal.		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)		
COXIELLA BURNETII; LYSOZYME; IMMUNE RESPONSE; SOLUBLE PHASE I ANTIGEN		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number)		
<p>Pretreatment of guinea pigs with lysozyme prior to vaccination with the phase I antigen of <u>Coxiella Burnetii</u> enhanced antibody response and protection against challenge. An observed effect on macrophage migration suggests that the role of lysozyme includes stimulation of cell-mediated immunity.</p>		

DD FORM 1 JAN 73 1473

EDITION OF 1 NOV 65 IS OBSOLETE

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

AD A090038

DDC FILE COPY

DTIC  
ELECTE  
OCT 8 1980  
A

80 10 01 08

405039

Effect of Lysozyme on the Immune Response of Guinea Pigs to the Soluble  
Phase I Antigen of Coxiella burnetii

R. F. WACHTER AND G. P. BRIGGS

U. S. Army Medical Research Institute of Infectious Diseases  
Fort Detrick, Frederick, Maryland 21701

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council. The facilities are fully accredited by the American Association for Accreditation of Laboratory Animal Care.

The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.

## SUMMARY

Pretreatment of guinea pigs with lysozyme prior to vaccination with the phase I antigen of Coxiella burnetii enhanced antibody response and protection against challenge. An observed effect on macrophage migration suggests that the role of lysozyme includes stimulation of cell-mediated immunity.

Accession No.	<input checked="checked" type="checkbox"/>
NTIS	<input type="checkbox"/>
ERIC	<input type="checkbox"/>
Other	<input type="checkbox"/>
Circulation	
Date	
Author	
Title	
Subject	
Notes	
A	

In tests to determine the effect of enzymes on the properties of the soluble phase I antigen of Coxiella burnetii, we observed that guinea pigs vaccinated with lysozyme-treated antigen had higher antibody titers and were more resistant to Q fever challenge than those given untreated antigen. (R. F. Wachter and G. P. Briggs, Abstr. Annu. Meet. Am. Soc. Microbiol. 1979, E103, p. 71). Continued investigation suggested that the enhancement of immunogenicity might be attributed to an adjuvant action of lysozyme rather than to enzymatic modification of the antigen. Results presented in this report suggest that lysozyme may increase protection by influencing both cellular immune and humoral responses.

In a series of five similar, but not identical, experiments, guinea pigs (8 or 10/group for a total of 92) were inoculated subcutaneously (s.c.) with two doses, 14 days apart, of antigen only or of lysozyme followed by antigen 4 or 5 h later. Saline and lysozyme control groups (a total of 64 guinea pigs) were included. In some additional tests we varied the time of administration of lysozyme relative to antigen. A dialyzed trichloroacetic acid (TCA) extract of concentrated, partially purified phase I C. burnetii, Henzerling strain, was employed as the antigen. Lysozyme (3 x crystalline egg white, Sigma Chemical Co.) was administered at both the first and second dose interval. Doses of antigen ranged from 2 to 14  $\mu$ g of protein, as determined by the Lowry method (6); doses of lysozyme ranged from 12.5 to 250  $\mu$ g. Doses used in each test are listed with Figure 1. Serum samples collected 14 days after the second inoculation were assayed for antibody by the microagglutination (MA) (2) and complement-fixation (CF) (1) tests. Guinea pigs were challenged intraperitoneally 28 to 45 days after the second dose with  $5 \times 10^5$  median infectious doses of phase I C. burnetii.

Temperatures were recorded once daily for 10 days; animals with temperatures  $40.0^{\circ}\text{C}$  for two or more consecutive days were considered unprotected.

The effect of pretreatment of guinea pigs with lysozyme on protection against Q fever by the phase I antigen is indicated in Figure 1. Data shown represent the mean of five tests. Doses of antigen and lysozyme employed in individual tests are listed. No optimal dosage combination was found; lower dose levels were as effective as higher levels. Fifty-nine percent of 46 guinea pigs that received antigen only were protected compared to 83% of 46 that received lysozyme prior to antigen ( $P < 0.02$ ). The time of administration of lysozyme relative to antigen appeared to be important: in a single experiment, lysozyme injected 24 or 48 h before antigen reduced the level of protection. In several other tests, administration of lysozyme and antigen at the same time, but at different sites, or of a mixture of lysozyme and antigen, either had no effect or reduced protection. Since this did not confirm our earlier observation with enzymatically-treated antigen (mentioned above), perhaps in the earlier enzyme experiments in which the lysozyme-antigen mixture was incubated at  $37^{\circ}\text{C}$  for 18 h, enhanced immunogenicity resulted from enzymatic alteration of the antigen, or from a combination of adjuvant effect of lysozyme with modified antigen.

For the same guinea pigs referred to in Figure 1 the effect of lysozyme on antibody response was determined on sera collected 14 days after the second dose. Figure 2 shows the geometric mean titers and percent animals responding for phase I and II MA antibodies and phase II CF antibody (phase I CF antibody is not produced at detectable levels from immunization with the phase I antigen). The doses for individual tests are the same as listed with Figure 1. The most pronounced difference

was seen with phase II CF antibody ( $P < 0.001$ ); differences for MA-I and MA-II antibody titers were also significant,  $P < 0.05$  and  $P < 0.01$ , respectively.

To investigate the possibility that lysozyme increased protection by stimulation of cellular immune mechanisms, we applied the macrophage migration-inhibition (MMI) technique to peritoneal cells from 4 groups of guinea pigs (4/group). Comparison was made between one group that received two doses, 2.0 and 6.0  $\mu\text{g}$  (protein) of antigen only, 14 days apart, and a group that received lysozyme, 50 and 250  $\mu\text{g}$ , 5 h before each dose of antigen. Peritoneal exudate cells were harvested, processed, and employed in the agarose droplet method of Harrington and Stastny (3) as applied by Kishimoto and Burger (4) to detect direct MMI. Cells were collected 4 days after intraperitoneal injection of 25 ml of sterile sodium caseinate. Half of the animals were started on test, i.e., given caseinate, one week, and half 2 weeks, after the second dose of antigen. In the absence of apparent differences, results from the 2 time periods were combined for purposes of analysis and presentation. Twenty replicate agarose droplets containing exudate cells were prepared from the cells harvested from each guinea pig. Subsets of 5 droplets each were overlaid with 0.2 ml of medium 199 (with calf serum) or with 0.2 ml of medium containing (a) 100  $\mu\text{g}/\text{ml}$  lysozyme, (b) 20  $\mu\text{g}/\text{ml}$  phase I antigen, or (c) 100  $\mu\text{g}/\text{ml}$  lysozyme and 20  $\mu\text{g}/\text{ml}$  antigen. Cultures were incubated, droplets examined, and migration inhibition calculated as described by Kishimoto and Burger (4).

The migration-inhibition of macrophages from guinea pigs that received antigen only (Fig. 3A) was much less than the inhibition of macrophages from animals that received lysozyme prior to antigen (Fig. 3B). Also, inhibition observed in subsets of droplets in the test system where

lysozyme plus antigen were employed as additives was substantially greater than in subsets with antigen alone; this was especially pronounced with macrophages from guinea pigs that received the lysozyme-antigen regimen. Also in this group, lysozyme itself produced limited inhibition.

Active immunity to Q fever has been reported to depend on both humoral and cellular responses (5). Other recent research has indicated that cellular immune mechanisms are exclusively responsible for protection against Q fever (M. S. Ascher, P. B. Jahrling, D. G. Harrington, R. A. Kishimoto, and V. G. McGann, Submitted to Clin. Exp. Immunol., 1980). The increase in CF antibody and the effect on macrophage-migration, which we have observed, suggest that the role of lysozyme in enhancing protection in the guinea pig host against Q fever could include both a stimulation of humoral response and cell-mediated immunity.



## LITERATURE CITED


1. Casey, H. L. 1965. Standardized diagnostic complement fixation method and adaptation to micro test. II. Adaptation of the LBCF method to microtechnique, p. 31-34. Public Health Monograph No. 74. U.S. Government Printing Office, Washington, D.C.
2. Fiset, P., R. A. Ormsbee, R. Silberman, M. Peacock, and S. H. Spielman. 1969. A microagglutination technique for detection and measurement of rickettsial antibodies. *Acta Virol.* 13:60-66.
3. Harrington, J. T., Jr., and P. Stastny. 1973. Macrophage migration from an agarose droplet: development of a micromethod for assay of delayed hypersensitivity. *J. Immunol.* 100:752-759.
4. Kishimoto, R. A., and G. T. Burger. 1977. Appearance of cellular and humoral immunity in guinea pigs after infection with Coxiella burnetii administered in small particle aerosols. *Infect. Immun.* 16:518-521.
5. Kishimoto, R. A., J. W. Johnson, R. H. Kenyon, M. S. Ascher, E. W. Larson, and C. E. Pedersen, Jr. 1978. Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine. *Infect. Immun.* 19:194-198.
6. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193:265-275.

## FIGURE LEGENDS


FIG. 1. Effect of pretreatment of guinea pigs (n = 46) with lysozyme on protection against Q fever by phase I antigen of C. burnetii. Mean of 5 tests. Antigen (µg protein) employed for first and second doses, respectively, for tests 1 through 5: 3.5, 3.5; 3.5, 7.0; 3.5, 14; 7.0, 7.0; 2.0 6.0. Lysozyme (µg) employed for first and second doses, respectively, for tests 1 through 5: 12.5, 12.5; 25, 25; 12.5, 25; 12.5, 25; 50, 250.

FIG. 2. Effect of pretreatment of guinea pigs (n = 46) with lysozyme on antibody response to phase I antigen of C. burnetii. Mean of same 5 tests and same doses as for Figure 1.

FIG. 3. Migration inhibition of macrophages from guinea pigs vaccinated with phase I antigen of C. burnetii, with and without prior administration of lysozyme. (A) Antigen alone (n = 4). (B) Antigen + lysozyme (n = 4).



ANTIBODY	TREATMENT		GEO. MEAN TITER
	ANTIGEN	LYSOZYME	
PHASE II	+		4.5
CF	+	+	12.2
PHASE I	+		3.9
MA	+	+	6.3
PHASE II	+		28.6
MA	+	+	39.8



# HEADQUARTERS, USAMRIID

2833 . . . . . Admin  
 . . . . . COL Barquist  
 . . . . . Connie Brown . . . . 8

2227 . . . . . COL Spertzel

2772 . . . . . Dr. Beisel  
 . . . . . Frances Byrd . . . . 24

2285 . . . . . Mr. Patrick  
 . . . . . Betty Swope . . . . 34

7373 . . . . . Mr. Kuhne

## ADMINISTRATIVE DIVISION

2868 . . . . . LTC Pedersen . . . . 45  
 . . . . . Shirley Young . . . . 47

2588 . . . . . MAJ Hilt . . . . . 43  
 . . . . . Mr. Everly . . . . . 46  
 . . . . . Karen Forney . . . . 36  
 . . . . . Betty Eckstine . . . . 41  
 . . . . . Jodi Davis . . . . . 31  
 . . . . . SP5 Gayadeen . . . . 42

2645 . . . . . 1LT Zusi . . . . . 35

2414 . . . . . Chief Med NCO . . . 20

7335 . . . . . SGT Shields . . . . . 29  
 . . . . . SP5 Pritts . . . . . 27  
 . . . . . Sue Grove . . . . . 25  
 . . . . . SSG Myers . . . . . 26  
 . . . . . Cindy Harts . . . . . 26  
 . . . . . Receptionist . . . . 23

2720 . . . . . Library . . . . . 48  
 . . . . . Ruth Janssen  
 . . . . . SP4 Urgolites

7381 . . . . . Editor  
 . . . . . Phebe Summers . . . 40

Med Illustrations  
 PVC Geeston . . . . . 51

Typing Pool  
 Joyce King . . . . . 55

7514 . . . . . Computer Sciences  
 . . . . . 2LT Chance  
 . . . . . Glen Higbee

2241/2476  
 . . . . . Orderly Room  
 . . . . . 1LT Garrett  
 . . . . . SFC Kelly

2698 . . . . . MAIN CONF ROOM . . . 52

# AEROBIOLOGY DIV

(7453)  
 Mrs. Hulme  
 NCOIC-SFC Robinson

# ANIMAL RESOURCES DIV

(7221)  
 Mrs. Ebberts  
 NCOIC-SSG Zeek

# BACTERIOLOGY DIV

(7341)  
 Miss Hill  
 NCOIC-SSG Smith

# LOGISTICS DIV

(7196)  
 Mrs. Milyard (Adm-44)  
 NCOIC-SFC Smith, J.

# MEDICAL DIVISION

(7281)  
 Mrs. Jewell  
 NCOIC-SFC Ellison

# PATHOLOGY DIVISION

(7211)  
 Mrs. Culler  
 NCOIC-SFC Hines

Chief: Mr. Larson  
 LTC Brown

Chief: LTC Rozmarek

LTC Montrey  
 MAJ Jaak, G.  
 CPT Donovan  
 CPT McNamee  
 CPT Stokes

Chief: COL H. Lund

LTC Lowry  
 MAJ Friedlander,  
 MAJ Ristroph  
 CPT Huggins  
 CPT Knudson  
 CPT Mikesell

Chief: LTC LaLuzerne (Adm-28)

CPT Daley-7121  
 Mr. Tumlinson-7401

Acting

Chief: MAJ Ostroy  
 MAJ Gosgriff  
 MAJ McGookin  
 CPT Bartel  
 CPT Fialkowski  
 CPT Stoeck  
 CPT Youngblood

Chief: COL DePaoli

COL Metzger  
 MAJ Callis  
 MAJ Hall  
 MAJ Lewis  
 MAJ Macasae  
 MAJ Morrissey  
 MAJ Stone  
 CPT Brennecke  
 CPT Copeland  
 CPT Jans, N.  
 CPT Knutsen  
 CPT Ross  
 1LT Dreier

# PHYSICAL SCIENCE DIV

(7181)  
 Mrs. Arnold  
 NCOIC-SFC Linderman

# VIROLOGY DIV

Mrs. Rosse - 7241  
 Mrs. Kline - 7244  
 NCOICs: SFC Cannon-7465  
 SSG Sierleja-7241

Chief: COL Eddy-7465

Dept of Viral  
 Pathogenesis &  
 Immunology 7465  
 LTC Lupton 7244  
 LTC Peters 7244  
 CPT Anderson 7244  
 CPT LaBarre 7244

Dept of Viral

Biology 7244  
 MAJ Meadors 7244  
 CPT Erick 7241  
 CPT Rice 7241  
 CPT Urbanski 7241

Dept of Arboviral

Entomology 7241  
 MAJ Bailey 7241  
 CPT Gargan 7241  
 CPT Hoch 7241  
 1LT Elias 7241

Dept of Antiviral

Studies 7244  
 MAJ Kastello 7244  
 MAJ Wannarka 7244

# FREQUENTLY CALLED NUMBERS

Building Engineers 7373  
 Clinical Lab 7351  
 Dental Clinic 2423  
 Dispensary 7175  
 Health Physics 7281  
 Med Maintenance 7401  
 Med Supply 7121  
 Optometry Clinic 7271  
 Ward 200 7361  
 X-Ray 2500

